Get notifications in MyBN when activity occurs.

Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. The lead product candidate is CAVATAKTM, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21), now being evaluated in Phase 1 and 2 clinical trials.

Contact Details

Suite 305, Level 3, 66 Hunter Street, SYDNEY NSW 2000
02 9988 4000

News Articles

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options